Correspondence 0001140361-23-019406 from Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc.
Date: April 20, 2023 · CIK: 0000748592 · Accession: 0001140361-23-019406
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271279
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Lauren Hamill Eterna Therapeutics Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) Filed April 17, 2023 File No. 333-271279
Dear Ms. Hamill:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 5:00 p.m. on April 24, 2023, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Eterna Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
Eterna Therapeutics Inc.
1035 Cambridge Street, Suite 18A
Cambridge, MA 02141
April 20, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Lauren Hamill
RE:
Eterna Therapeutics Inc. (the “Company”)
Registration Statement on Form S-1 (the “Registration Statement”)
Filed April 17, 2023
File No. 333-271279
Dear Ms. Hamill:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of
effectiveness of the Registration Statement so that such Registration Statement will become effective as of 5:00 p.m. on April 24, 2023, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Eterna Therapeutics Inc.
By:
/s/ Matthew Angel
Name: Matthew Angel
Title: Chief Executive Officer and President